[{"from": "human", "value": "Could you provide a description of this molecule? [C][C@H1][C@@H1][Branch2][S][=N][C@@][Branch2][S][Branch1][C][C@@H1][Branch1][Ring2][O][Ring1][=Branch1][O][C@H1][C@H1][C][=Branch1][C][=O][N][C@@H1][Branch2][=C][=N][C][=C][Branch1][=N][C][=Branch1][=Branch2][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][O][O][C][=C][Branch2][=N][#Branch1][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C@H1][Branch1][=Branch2][C][=Branch1][C][=O][N][Ring2][Ring1][#Branch1][N][C][=Branch1][C][=O][C@H1][C][=C][C][=Branch2][#Branch1][#Branch2][=C][Branch2][Ring1][=Branch1][C][=Branch1][Ring2][=C][Ring1][=Branch1][O][C][=C][Branch1][#Branch2][C][=C][Ring2][Ring2][#Branch1][C][=C][Ring1][=Branch1][Cl][O][C@H1][C@@H1][Branch1][P][C@H1][Branch1][=N][C@@H1][Branch1][=Branch2][C@H1][Branch1][Ring2][O][Ring1][=Branch1][C][O][O][O][O][C@H1][C][C@][Branch1][N][C@H1][Branch1][Branch2][C@@H1][Branch1][Ring2][O][Ring1][=Branch1][C][O][Branch1][C][C][N][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Cl][O][C][=C][Branch2][Branch1][Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C@H1][Branch2][Ring2][O][C@H1][Branch2][Ring1][#Branch1][C][=Branch1][C][=O][N][C@H1][Branch1][=Branch2][C][=Branch1][C][=O][N][Ring2][=Branch1][Ring1][C][C][=Branch1][C][=O][N][N][C][=Branch1][C][=O][C@@H1][Branch1][#Branch1][C][C][Branch1][C][C][C][N][C][O][Cl][O][C][=Branch1][C][=O][O][Branch1][C][C][N][O]"}, {"from": "gpt", "value": "The molecule is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.  On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections."}]